GlassScriptPhysician profile
George Liwei Chen
NPI 1366757775
$7,026.35
in general payments reported to CMS, 2019-2025
17 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $37.79 · 2022: $375 · 2023: $4,396 · 2024: $575 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,782 · Food and Beverage: $1,901 · Gift: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,782.00 |
| Food and Beverage | $1,900.97 |
| Gift | $810.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,169.95 | 2023-2025 | |
| Sekisui Diagnostics LLC | $1,185.00 | 2022-2025 | |
| Astellas Pharma US INC | $395.36 | 2019-2025 | Xospata, Cresemba |
| Abbvie INC. | $274.97 | 2025 | |
| Incyte Corporation | $168.14 | 2024-2025 | Jakafi, Jakafi, Niktimvo |
| Jazz Pharmaceuticals INC. | $148.62 | 2023 | |
| Sanofi US Services INC. | $122.69 | 2025 | |
| Janssen Biotech, INC. | $121.51 | 2024 | Tecvayli, Darzalex |
| Pfizer INC. | $118.47 | 2025 | |
| Daiichi Sankyo INC. | $88.57 | 2024 | Vanflyta |
| Ucb, INC. | $82.38 | 2019-2023 | Briviact |
| Sobi, INC | $60.23 | 2025 | |
| Merck Sharp & Dohme LLC | $34.73 | 2025 | Zerbaxa, Prevymis |
| Syndax Pharmaceuticals, INC. | $30.63 | 2025 | |
| Seagen INC. | $25.10 | 2023 | Adcetris |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.